Skip to content

Dark Chocolate and Intestinal Motility

Effects of Dark Chocolate on Gastrointestinal Motility in Healthy Subjects

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03841578
Acronym
CHOCO-mot
Enrollment
10
Registered
2019-02-15
Start date
2019-03-01
Completion date
2020-03-01
Last updated
2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Motility

Keywords

Dark chocolate, gastrointestinal motility

Brief summary

Following food intake, the body activates several processes to degrade and digest it. Studies show that there is an adaptation of gastric emptying and gastrointestinal motility to a food component; therefore, considering the intestinal adaptation to chocolate, the effect on gastrointestinal motility in relation to the intake of chocolate will be investigated. The organoleptic perceptions of dark chocolate will also be analyzed to evaluate the appreciation of the product ingested by the subject.

Detailed description

Chocolate, the main product deriving from cocoa beans (Theobroma cacao, from the Greek food of the gods) has its origin in Mexico, where Maya, Inca and Aztecs practiced its cultivation, has for centuries been appreciated for its pleasant taste and its beneficial health effects. Chocolate is the most sought-after food worldwide, and currently its consumption has increased considerably with a wide availability of products on the market. Dietary choices are strongly influenced by the taste and consistency of foods. Fat is largely responsible for the sensory properties of many foods and, therefore, contribute greatly to the pleasure of eating. Dark chocolate consists of ≈43% of lipids, mainly represented by cocoa butter. Cocoa butter is composed of an average of 33% of oleic acid, 25% of palmitic acid and 33% of stearic acid. Another component of chocolate is polyphenols, in particular flavonoids, substances with numerous beneficial effects for health, including antihypertensive, anti-inflammatory, antithrombotic, metabolic and prebiotic activity playing a role in the change of human intestinal microbiota. Recent scientific studies show an inverse correlation between the intake of flavonoids in the diet and the incidence of diabetes, such as to hypothesize the use of foods rich in flavonoids as potential food supplements in the management of diabetes. The cocoa flavonoids can bring benefits to the insulin-resistance condition by improving endothelial function, modifying glucose metabolism and reducing oxidative stress, which is considered the main cause of insulin resistance. In healthy individuals and even in patients with moderate cardiovascular risk, regular intake of flavonoids improves levels of cardiovascular biomarkers, reducing serum LDL cholesterol concentrations and triglycerides and increasing HDL cholesterol concentrations. The flavonoids present in cocoa may also inhibit platelet aggregation by down-regulation of the cellular synthesis of eicosanoids. Chocolate is an effective alternative for increasing fiber intake at recommended levels; in addition, it reduces intestinal transit time by increasing peristaltic movements.

Interventions

DIETARY_SUPPLEMENTHealthy

25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat

Sponsors

University of Bari
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Intervention model description

10 healthy subjects (controls) undergoing organoleptic assessment and gastrointestinal motility study

Eligibility

Sex/Gender
ALL
Age
25 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 25-35 years old * Able to sign an informed consent

Exclusion criteria

* Refuse to sign an informed consent * Diagnosis of organic diseases, including neoplastic inflammatory or cardiovascular diseases * Drugs able to influence the gastrointestinal tract or interfering with symptoms * Pregnancy * Presence of diseases with a prognosis inferior to a year * Hypersensitivity to chocolate or its components

Design outcomes

Primary

MeasureTime frameDescription
Organoleptic assessment1 dayAll subjects (n=10, matched per gender) will undergo a subjective organoleptic assessment of dark chocolate, based on a standard semi-quantitative scale (ranging 1-5) and a quantitative visual analogue scale (VAS, ranging from 0 to 100 on a horizontal line), to evaluate the visual, auditory, olfactory, gustatory and tactile aspects.
Gastrointestinal motility1 dayAll subjects (n=10, matched per gender) will be assessed for gastrointestinal motility in fasting state to monitor gastric empting, gallbladder empting (ultrasound) and oro-cecal transit time (H 2 lactulose BT), at baseline and at 5 minutes intervals during the firsts 30 minutes, and at 15 minutes intervals during the remaining 90 minutes, for a total of 2 hours of observations.

Countries

Italy

Contacts

Primary ContactPiero Portincasa, MD, PhD
piero.portincasa@uniba.it+393284687215

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026